Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Mantle Cell Lymphoma
Last updated June 27, 2017
Status:
Concluded with an LOI
Manufacturer:
UCB Canada Inc.
Indication:
Parkinson's disease
Last updated June 23, 2017
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Rheumatoid Arthritis and Ankylosing Spondylitis
Last updated June 19, 2017
Status:
Concluded with an LOI
Manufacturer:
Eisai Limited
Indication:
Differentiated Thyroid Cancer
Last updated June 16, 2017
XigDuo (dapagliflozin/metformin hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated June 13, 2017
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Non-Hodgkin's Lymphoma and Multiple Myeloma
Last updated June 6, 2017
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Acute Lymphoblastic Leukemia (ALL)
Last updated May 24, 2017
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Ulcerative Colitis
Last updated May 23, 2017
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Metastatic Colorectal Cancer
Last updated May 22, 2017
Cotellic - Zelboraf (cobimetinib - vemurafenib)
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Metastatic Melanoma
Last updated May 11, 2017